|
|
Post by morfu on Mar 13, 2020 11:52:25 GMT -5
Is there any discussion somewhere about the Corona virus being more deadly for people with preexisiting conditions and Afrezza users having lower HbA1C values? Can that simply be estimated to an increased survival chance? If so, how big is the difference? Regardless, I expect diabetes patients being in better compliance these days.
|
|
|
|
Post by awesomo on Mar 13, 2020 12:01:31 GMT -5
Is there any discussion somewhere about the Corona virus being more deadly for people with preexisiting conditions and Afrezza users having lower HbA1C values? Can that simply be estimated to an increased survival chance? If so, how big is the difference? Regardless, I expect diabetes patients being in better compliance these days.
It is much more dangerous for people with pre-existing conditions as any underlying condition challenges the immune system. So yes, I would say diabetics should especially stress managing their glucose levels during this pandemic. |
|
|
|
Post by ktim on Mar 13, 2020 12:13:04 GMT -5
Ha Ha ... that wasn't me that said that. I just told that person to ignore you ... and now you feel guilty and come crying to me. So sad ... So bad. BTW, how much do you get paid ... and how can I sign on? But, that's mytakeonit Oh, just advice you were giving to others but don't do yourself... ok. Though it might still be nice if you tried adhering to your own advice. As for payment, let's just say if you have to ask you probably wouldn't qualify for it. It's massive though, "they" did have to put a satellite internet link into the yacht they gave me, neither of which are cheap. Isn't it ego boosting that they are spending so much to influence you  |
|
|
|
Post by prcgorman2 on Mar 13, 2020 13:28:55 GMT -5
Is there any discussion somewhere about the Corona virus being more deadly for people with preexisiting conditions and Afrezza users having lower HbA1C values? Can that simply be estimated to an increased survival chance? If so, how big is the difference? Regardless, I expect diabetes patients being in better compliance these days.
It is much more dangerous for people with pre-existing conditions as any underlying condition challenges the immune system. So yes, I would say diabetics should especially stress managing their glucose levels during this pandemic. And how is compliance in 3rd world countries where distribution, needles, and refrigeration present real problems? I've been wondering more how much value there is to almost giving away Afrezza in foreign markets, and given the challenges with PBMs, maybe greatly expanding the Eagle pharmacy approach. To heck with giving the discount to the PBMs, give it to the PWDs instead. |
|
|
|
Post by ktim on Mar 13, 2020 15:16:23 GMT -5
It is much more dangerous for people with pre-existing conditions as any underlying condition challenges the immune system. So yes, I would say diabetics should especially stress managing their glucose levels during this pandemic. And how is compliance in 3rd world countries where distribution, needles, and refrigeration present real problems? I've been wondering more how much value there is to almost giving away Afrezza in foreign markets, and given the challenges with PBMs, maybe greatly expanding the Eagle pharmacy approach. To heck with giving the discount to the PBMs, give it to the PWDs instead. Is there currently a limit on the Eagle pharmacy program? I know initially they put a limit on it, but I thought they were now accepting anyone that needed it. |
|
|
|
Post by agedhippie on Mar 13, 2020 19:39:43 GMT -5
It is much more dangerous for people with pre-existing conditions as any underlying condition challenges the immune system. So yes, I would say diabetics should especially stress managing their glucose levels during this pandemic. And how is compliance in 3rd world countries where distribution, needles, and refrigeration present real problems? I've been wondering more how much value there is to almost giving away Afrezza in foreign markets, and given the challenges with PBMs, maybe greatly expanding the Eagle pharmacy approach. To heck with giving the discount to the PBMs, give it to the PWDs instead. Third world countries can barely afford insulin at all never mind RAA or Afrezza. In parts of the world a 10mL vial of Regular costs $6 and that is borderline unaffordable there. Afrezza or RAA is definitely a first world problem! |
|
|
|
Post by boytroy88 on Mar 17, 2020 8:11:21 GMT -5
Feel free to add more, I am sure I did not cover all of them. MannKind Catalysts for 2020-2021š„ Pediatric Clinical Trial š„ Philip Levin Clinical Trial š„ Dexcom Clinical Trial š„ United Therapeutics TreT Clinical Trial š„ India Clinical Trial š„ BluHale Pro Launch š„ Australia Regulatory Filing Approval š„ FDA Approval on Advanced Expiration Dating š„ United Therapeutics Second Molecule š„ United Therapeutics Milestones š„ Pipeline Partnership š„ Pipeline Expansion š„ Further Debt Reduction š„ Increased International Expansion š„ Brazil Afrezza Sales š„ Receptor Life Sciences Would the morning's news count as one? |
|
|
|
Post by mango on Mar 17, 2020 8:27:16 GMT -5
|
|
|
|
Post by mango on Mar 17, 2020 10:04:16 GMT -5
"...prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19."
"Other collaborations are being actively explored at this time."
I wonder what other respiratory viral infections MannKind is actively looking at, particularly, those for partnerships/collaborations.
Exciting times ahead.
|
|
|
|
Post by mango on Mar 17, 2020 10:19:06 GMT -5
"MannKind is committed to joining the global effort to overcome the COVID-19 crisis. MannKindās formulation and drug development expertise as well as its excess manufacturing capacity will be deployed as necessary to help protect humankind from this global health crisis."
-------------------------------------------------------------------
Response: Oh, hell yes.
And, I love that MannKind is finally advertising their technology and capabilities. We are a badass company, time to let the world know it!
-------------------------------------------------------------------
Formulations for Pulmonary Delivery
MannKindās TechnosphereĀ® technology is an innovative, dry-powder formulation technology that allows medication to be delivered to the lungs. MannKind has successfully prepared Technosphere formulations of anionic and cationic drugs, hydrophobic and hydrophilic drugs, proteins, peptides and small molecules. Technosphere powders are based on a proprietary excipient, fumaryl diketopiperazine (FDKP), which is a pH-sensitive organic molecule that self-assembles into small particles under acidic conditions. Active pharmaceutical ingredients can be loaded onto these particles, which are then dried to powder form. The resulting powder has a consistent and narrow range of particle sizes with good aerodynamic properties that enable efficient delivery deep into the lungs. Technosphere powders dissolve quickly when the particles contact the moist lung surface with its neutral pH, releasing the drug molecules to diffuse across a thin layer of cells into the arterial circulation, bypassing the liver to provide excellent systemic exposure.
Drug Delivery Devices
MannKind has also created an innovative line of breath-powered, dry powder inhalers. Its inhalers are easy to use, cost-effective and can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format. Both the reusable and single-use inhaler formats use the same internal air-flow design. Being breath-powered, our inhalers require only the patientās inhalation effort to deliver the powder. The inhalers are engineered to produce an aggressive airstream that de-agglomerates the powder while keeping the powder moving relatively slowly. This slow-moving powder effectively navigates the patientās airways to reach the deep lung with minimal deposition at the back of the throat. MannKindās inhalers show very little change in performance (i.e., efficient cartridge emptying) over a wide range of inhalation efforts.
Manufacturing Capability
MannKindās 328,000 square foot R&D and manufacturing facility is located in Danbury, Connecticut and has a full range of development and manufacturing capabilities, including analytical, chemical, formulation, filling and packaging. The facility houses two 61 square meter lyophilizers and has sufficient filling capacity to produce more than 300 million cartridges of inhaled drug annually. The quality management systems of the facility have been certified to be in conformance with the ISO 13485 and MD-SAP standards and was inspected most recently by the U.S. Food and Drug Administration in June 2018, at which time there were no inspectional observations.
|
|
|
|
Post by prcgorman2 on Mar 17, 2020 11:06:41 GMT -5
"...prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19." "Other collaborations are being actively explored at this time." I wonder what other respiratory viral infections MannKind is actively looking at, particularly, those for partnerships/collaborations. Exciting times ahead. Are any of the oral anti-viral compounds a candidate for TS? Would there be any advantage to inhaled delivery? |
|
|
|
Post by mango on Mar 17, 2020 11:14:26 GMT -5
"...prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19." "Other collaborations are being actively explored at this time." I wonder what other respiratory viral infections MannKind is actively looking at, particularly, those for partnerships/collaborations. Exciting times ahead. Are any of the oral anti-viral compounds a candidate for TS? Would there be any advantage to inhaled delivery? Yes, some advantages would be localized delivery to the target organ, which usually allows for a lower dose than is necessary with systemic (oral and injection), and thus fewer and less severe adverse effects/side-effects. It also means it bypasses first-pass metabolism (unlike oral and injection), and also would mimic intra arterial administration. All this likely resulting in a significantly more effective, safe and tolerable treatment. |
|
|
|
Post by ktim on Mar 17, 2020 11:24:42 GMT -5
"...prioritizing work on new compounds that may have the potential to address the morbidity and mortality associated with respiratory viral infections, such as COVID-19." "Other collaborations are being actively explored at this time." I wonder what other respiratory viral infections MannKind is actively looking at, particularly, those for partnerships/collaborations. Exciting times ahead. Are any of the oral anti-viral compounds a candidate for TS? Would there be any advantage to inhaled delivery?Do existing anti-virals ordinarily use extended release formulations? If that is necessary then it might be hard to achieve the same with inhaled. If duration of action isn't a question then targeted concentration in respiratory system might be beneficial. At least those are general issues I might anticipate without knowing specifics of the API. |
|
|
|
Post by nylefty on Mar 28, 2020 13:18:04 GMT -5
apnews.com/b21a296383694c6726d03e027134daf1RIO DE JANEIRO (AP) ā Even as coronavirus cases mount in Latin Americaās largest nation, Brazilian President Jair Bolsonaro has staked out the most deliberately dismissive position of any major world leader, calling the pandemic a momentary, minor problem and saying strong measures to contain it are unnecessary. Bolsonaro says his response to the disease matches that of President Donald Trump in the U.S., but the Brazilian leader has gone further, labeling the virus as āa little fluā and saying state governorsā aggressive measures to halt the disease were crimes.
|
|
|
|
Post by mango on Mar 28, 2020 14:56:42 GMT -5
apnews.com/b21a296383694c6726d03e027134daf1RIO DE JANEIRO (AP) ā Even as coronavirus cases mount in Latin Americaās largest nation, Brazilian President Jair Bolsonaro has staked out the most deliberately dismissive position of any major world leader, calling the pandemic a momentary, minor problem and saying strong measures to contain it are unnecessary. Bolsonaro says his response to the disease matches that of President Donald Trump in the U.S., but the Brazilian leader has gone further, labeling the virus as āa little fluā and saying state governorsā aggressive measures to halt the disease were crimes. Wrong thread. |
|
